Latest news

Thumbnail image for EU approves Repatha for reduction of CV risk

EU approves Repatha for reduction of CV risk

The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).

23rd May 2018

Thumbnail image for Novo’s Refixia beats rival in head to head trial

Novo’s Refixia beats rival in head to head trial

Novo Nordisk’s Refixia has come out on top in a head to head study assessing its effect in patients with the bleeding disorder haemophilia B against Swedish Orphan Biovitrum’s recombinant factor IX-Fc fusion protein (rFIXFc).

22nd May 2018

Thumbnail image for US green light for AZ’ Lokelma

US green light for AZ’ Lokelma

US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia - elevated potassium levels in the blood - in adult patients.

21st May 2018

Thumbnail image for Data show ‘enduring’ benefits of GSK’s Nucala

Data show ‘enduring’ benefits of GSK’s Nucala

GlaxoSmithKline has released long-term data showing that its biologic Nucala significantly decreased exacerbations in patients with severe, eosinophilic asthma as well as improvement in disease control.

21st May 2018

Thumbnail image for EMA confirms risks of MS drug Zinbryta

EMA confirms risks of MS drug Zinbryta

The European Medicines Agency has concluded that the risks linked with use of Biogen and AbbVie's multiple sclerosis drug Zinbryta outweigh its benefits.

21st May 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download